Home / Going-concern warnings / Cardiff Oncology, Inc.
Filed 2026-08-11 路 Form 10-Q 路 Accession 0001193125-26-344545 micro
Price before filing: $1.03 (2026-08-10 close, split/dividend-adjusted)
Market cap at flag: $71.8M (2026-08-11) 路 Latest: $61.6M (2026-10-16)
| Window | CRDF | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +17.5% | -2.0% | +19.4% | 2026-09-10 |
| 90 days | pending | pending | until 2026-11-09 | |
| 180 days | pending | pending | until 2027-02-07 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"As of June 30, 2026, the Company had $ 34.5 million in cash, cash equivalents and short-term investments, which is not sufficient to meet its funding requirements for at least the next 12 months following the filing of this Form 10-Q. Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2026-06-30)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.